Petros Pharmaceuticals (PTPI) Competitors $0.03 0.00 (-8.88%) As of 03:58 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTPI vs. INM, TTNP, PLRZ, EVOK, LIPO, DRMA, VIVS, CMND, CANF, and ARTLShould you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include InMed Pharmaceuticals (INM), Titan Pharmaceuticals (TTNP), Polyrizon (PLRZ), Evoke Pharma (EVOK), Lipella Pharmaceuticals (LIPO), Dermata Therapeutics (DRMA), VivoSim Labs (VIVS), Clearmind Medicine (CMND), Can-Fite BioPharma (CANF), and Artelo Biosciences (ARTL). These companies are all part of the "pharmaceutical products" industry. Petros Pharmaceuticals vs. Its Competitors InMed Pharmaceuticals Titan Pharmaceuticals Polyrizon Evoke Pharma Lipella Pharmaceuticals Dermata Therapeutics VivoSim Labs Clearmind Medicine Can-Fite BioPharma Artelo Biosciences Petros Pharmaceuticals (NASDAQ:PTPI) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings. Which has more risk and volatility, PTPI or INM? Petros Pharmaceuticals has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Does the media favor PTPI or INM? In the previous week, InMed Pharmaceuticals had 2 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 2 mentions for InMed Pharmaceuticals and 0 mentions for Petros Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.32 beat Petros Pharmaceuticals' score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Petros Pharmaceuticals Neutral InMed Pharmaceuticals Neutral Is PTPI or INM more profitable? Petros Pharmaceuticals has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -168.87%. Petros Pharmaceuticals' return on equity of -78.22% beat InMed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Petros PharmaceuticalsN/A -78.22% -23.50% InMed Pharmaceuticals -168.87%-107.93%-82.97% Do institutionals and insiders believe in PTPI or INM? 12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 1.4% of InMed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable earnings and valuation, PTPI or INM? InMed Pharmaceuticals has lower revenue, but higher earnings than Petros Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPetros Pharmaceuticals$5.11M0.19-$8.16M-$119.000.00InMed Pharmaceuticals$4.60M0.72-$7.68M-$12.09-0.23 SummaryPetros Pharmaceuticals beats InMed Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTPI vs. The Competition Export to ExcelMetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$991K$784.82M$5.53B$9.03BDividend YieldN/A4.84%5.24%4.07%P/E Ratio-0.011.0927.1920.03Price / Sales0.19230.50414.39108.98Price / CashN/A23.4426.2128.59Price / Book0.016.237.925.55Net Income-$8.16M-$27.94M$3.17B$248.49M7 Day PerformanceN/A2.21%2.18%5.37%1 Month PerformanceN/A8.98%1.25%6.63%1 Year PerformanceN/A11.57%33.90%21.20% Petros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTPIPetros Pharmaceuticals0.6348 of 5 stars$0.03-8.9%N/A-99.7%$991K$5.11M-0.0120Gap DownINMInMed Pharmaceuticals1.0185 of 5 stars$3.25-3.8%N/A-44.9%$4.08M$4.60M-0.2710Analyst UpgradeGap DownTTNPTitan Pharmaceuticals0.085 of 5 stars$4.20-4.5%N/A-14.6%$4.02M$180K-0.9210Gap DownPLRZPolyrizonN/A$0.740.0%N/AN/A$3.94MN/A0.00N/APositive NewsGap DownEVOKEvoke PharmaN/A$2.60-1.1%N/A-58.3%$3.92M$10.25M-0.914Positive NewsLIPOLipella Pharmaceuticals1.3048 of 5 stars$0.87-3.6%N/A-78.8%$3.88M$536.36K-0.214DRMADermata Therapeutics1.8898 of 5 stars$0.59-3.2%$3.00+412.8%-71.8%$3.85MN/A-0.048Positive NewsGap UpVIVSVivoSim LabsN/A$1.47flatN/AN/A$3.82M$140K-0.1420Positive NewsCMNDClearmind Medicine0.6277 of 5 stars$0.90+1.2%N/A-30.5%$3.79MN/A-0.82N/ACANFCan-Fite BioPharma3.2749 of 5 stars$1.05+1.0%$14.00+1,233.3%-57.9%$3.72M$674K-0.598Gap UpARTLArtelo Biosciences2.9458 of 5 stars$13.27+95.4%$33.00+148.7%+34.8%$3.71MN/A-0.745Gap UpTrading HaltedHigh Trading Volume Related Companies and Tools Related Companies InMed Pharmaceuticals Competitors Titan Pharmaceuticals Competitors Polyrizon Competitors Evoke Pharma Competitors Lipella Pharmaceuticals Competitors Dermata Therapeutics Competitors VivoSim Labs Competitors Clearmind Medicine Competitors Can-Fite BioPharma Competitors Artelo Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTPI) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTPI Stock Alerts